Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis

Figure 3 Cumulative remission rate. A: Cumulative remission rate in patients who achieved clinical remission at week 8; B: Cumulative remission rates according to previous history of anti-tumor necrosis factor α agent failure (naive vs 1 failure vs ≥ 2 failure) in patients who achieved clinical remission at week 8.